Published 12 days ago • loading... • Updated 12 days ago

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

At the ASCO GU 2026 Conference, ImmVira Group announced trial expansion of MVR-T3011 to BCG‑naïve high-risk bladder cancer patients and presented preliminary data.
Amid global BCG shortages, Bacillus Calmette‑Guérin remains the standard of care for high-risk non‑muscle‑invasive bladder cancer patients, but many cannot access treatment due to scarcity and side effects.
In the interim analysis as of February 26, 2026, 18 BCG‑naïve high‑risk papillary Ta/T1 NMIBC patients showed 100% 3-month RFS with no treatment-related adverse events, according to the study data.
The company framed MVR‑T3011 as a promising alternative, with Dr. Grace Zhou saying `We are highly encouraged by the preliminary efficacy and safety data from the study`.
Its multi-route feasibility positions MVR‑T3011's proprietary "3‑in‑1" HSV‑1 design for broader development against bladder cancer, ninth most prevalent worldwide with about 75% NMIBC.

Insights by Ground AI

33 Articles

Bennington Banner

+32 Reposted by 32 other sources

Center

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects…

12 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year